Purpose: The aim of this study was to compare the incidence of focal thyroid incidentalomas on 18 F-fluorodeoxyglucose positron emission tomography/computed tomography ( 18 F-FDG PET/CT) in breast cancer patients with the incidence in healthy women, and to assess for any significant characteristics of the breast cancers in patients with concurrent focal thyroid incidentalomas. Methods: We retrospectively reviewed the medical records of 489 breast cancer patients and 286 healthy women who were evaluated with 18 F-FDG PET/CT between March 2010 and February 2012. We analyzed the images visually and obtained semiquantitative indices. Results: The overall incidence of focal thyroid incidentalomas was 9.4% (46/489) in breast cancer patients and 5.9% (17/286) in healthy patients (p< 0.01). Among 23 focal incidentalomas in breast cancer patients and five in healthy women with additional cytological and histological diagnoses, papillary thyroid carcinoma was diagnosed in 11 breast cancer patients (23.9%) and in two healthy patients (11.7%). Ductal carcinoma in situ (p= 0.03), estrogen receptor (ER) positivity (p< 0.01), progesterone receptor (PR) positivity (p< 0.01), and Ki-67 positivity (p< 0.01) were correlated with breast cancer patients with focal thyroid incidentalomas. Conclusion: Focal thyroid incidentalomas were more frequently detected with 18 F-FDG PET/CT in patients with breast cancer than in healthy women. Focal thyroid nodules incidentally found with 18 F-FDG PET/CT in breast cancer patients have a high risk of malignancy. ER positivity, PR positivity, Ki-67 positivity, and ductal carcinoma in situ correlated positively with 18 F-FDG PET/CT-detected focal thyroid incidentalomas.
INTRODUCTION
The overall reported incidence of 18 F-fluorodeoxyglucose positron emission tomography ( 18 F-FDG PET) or PET/computed tomography (PET/CT)-detected thyroid incidentalomas varies from 0.2% to 8.9%, whereas the presence of thyroid cancer in these incidental lesions can range from 8% to 64% [1, 2] . Thyroid incidentalomas may represent benign disease, primary malignancy, or metastases [3] . Both thyroid and breast cancers are more frequent in women than in men, and it has been suggested that estrogen plays a role in the tumorigenesis of both
cancers. Several studies have demonstrated that there is an increased risk of breast cancer in patients with thyroid dysfunction and thyroid cancer [4] . As 18 F-FDG PET/CT is widely used in the diagnosis, staging, and metastatic workups of patients with neoplastic disease, the incidence of 18 F-FDG PET-detected incidentalomas is increasing [5, 6] . In Korea, thyroid cancer is the most common female cancer, followed by breast cancer [7] . There have been few studies of 18F-FDG PET/CTdetected thyroid incidentalomas in breast cancer patients [1, 8] . Guidelines are needed to manage thyroid incidentalomas detected during treatment for breast cancer.
Our study aimed to evaluate (1) the incidence of focal thyroid incidentalomas identified on 18 F-FDG PET for breast cancer compared with the incidence in healthy women; (2) any correlation between the clinicopathological characteristics of breast cancers with concurrent focal thyroid incidentalomas; and (3) the malignant potential of 18 F-FDG PET/CT-detected focal thyroid incidentalomas.
METHODS

Patient selection
58 JungSunLee institute; breast cancer patients were enrolled through the breast care center and healthy subjects through our health promotion center.
During the study period, 531 female patients with primary breast cancer and 801 healthy subjects were evaluated with 18 F-FDG PET/CT.
The following exclusion criteria for breast cancer patients or healthy subjects were utilized in this study: (1) male sex, (2) distant metastasis at the time of diagnosis, (3) treatment with neoadjuvant chemotherapy, jection, a 3-minute static emission study was performed at the transmission position (early phase), another study for the delayed phase was performed 120 minutes after the injection, and whole body imaging was performed from the base of the skull to the mid thighs. Lowdose whole body CT was performed before the emission scan for CT attenuation correction instead of a transmission scan. These data were also used for anatomic localization of the PET emission image. The attenuation-corrected PET images were reconstructed with an or- To calculate the SUVmax, manually defined circular ROIs were drawn on the attenuation-corrected emission images throughout the axial plane on which a suspicious lesion could be delineated. We defined 18 F-FDG PET/CT-detected focal thyroid incidentalomas as the presence of focal FDG uptake in the thyroid including very tiny foci of FDG uptake with a definite nodule on the CT images ( Figure 1 ).
Immunohistochemical staining of breast cancer
Immunohistological staining for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) was performed using arrayed tissue blocks. Briefly, 5 μm-thick, formalin-fixed, paraffin-embedded tissue sections were obtained using a microtome, transferred to adhesive slides, and dried at 62°C for 30 minutes. Sections were incubated, using a benchmark au- shown as raw score ranging from 0% to 100% [9] . Samples were considered positive for HER2 when strong (3+) membranous staining was observed in at least 10% of tumor cells, whereas those with staining of grades 0 to 2+ were regarded as negative. Tissue samples of HER2 2+ breast cancers underwent silver in situ hybridization analysis. For practical considerations in a hospital setting, as a substitute for gene expression profiling, the use of immunohistochemical surrogate panels of ER, PR, and HER2 has been proposed to potentially differentiate between the subtypes [10] .
Cytological confirmation of 18 
F-FDG PET/CTdetected focal thyroid incidentalomas
Fine-needle aspiration biopsy (FNAB) is recommended, regardless of the size of the nodule, if it presents sonographic signs suggestive of a malignancy according to the guidelines of the National Cancer Institute [11] .
FNAB was performed with a 21-gauge needle on a 10 mL syringe under ultrasound guidance. A cytological diagnosis was made by experienced cytopathologists in our institution. Cytological diagnosis was as follows: (1) nondiagnostic (applies to specimens that are unsatisfactory due to blood, overlaid thick or air-dried smears, or an inadequate number of follicular cells); (2) benign; (3) atypia of undetermined significance (results of proliferating cell nuclear antigen cytology were not easily classified into benign, suspicious, or malignant categories); (4) follicular neoplasm (findings of high cellularity and scant or absent colloid); (5) suspicious for malignancy (only one or two characteristic features of papillary thyroid carcinoma were present, or a malignant diagnosis could not be made with certainty; (6) malignant (whenever the morphologic features were conclusive for malignancy) [12] .
Data collection
The following data were recorded for all breast cancer patients: age, body mass index, number of lymph node metastases, tumor size, his- 
Statistical analyses
The statistical analyses were performed using SAS version 8. 
RESULTS
Incidence of thyroid incidentalomas on 18
F-FDG PET/CT: comparisons between primary breast cancer patients and healthy female subjects The clinicopathological characteristics of primary breast cancer patients with an 18 
F-FDG PET/CT-detected thyroid incidentaloma
The breast cancer patients with focal thyroid incidentalomas (mean age, 52.9 years) was similar to them without focal thyroid incidentaloma (mean age, 51.2 years) (p = 0.27). The breast cancer histologic types in the group with thyroid incidentalomas were more often ductal carcinoma in situ compared with the group without thyroid incidentalomas (19.8% vs. 14.5%, p = 0.03) ( Table 1 ). The group with thyroid incidentalomas had more ER positivity (56.5% vs. 50.0%), PR positivity (50% vs. 39.3%), and Ki-67 positivity (95.6% vs. 50.2%) than the group without thyroid incidentalomas (p < 0.01) ( Table 1 ). HER2 overexpression was higher in the group without focal thyroid incidentalomas than in the group with focal thyroid incidentalomas (23.2% vs. 15.2%, p < 0.03). Tumor size, number of metastatic lymph nodes, lymphovascular invasion, extent of the intraductal component, and p53 expression were not different between the two groups ( Table 1) .
The SUVmax and cytological findings in thyroid incidentalomas
Aspiration was performed twice for each nodule. FNAB was performed in 23 of 37 focal thyroid incidentalomas (62.1%) in breast cancer and 5 of 12 thyroid incidentalomas (41%) in healthy subjects. The other 21 thyroid incidentalomas were diagnosed as benign nodular 
DISCUSSION
A focal thyroid lesion with significant uptake is likely to be malignant [13] , whereas several benign conditions, including nodular hyperplasia, multiple nodular goiter, benign follicular tumor, and chronic thyroiditis, also show a high SUV. Diffusely increased uptake in the thyroid gland favors several thyroidal disorders, including chronic thyroiditis, Graves' disease, diffuse goiter, and multinodular goiter [14, 15] . A strong relationship between breast malignancy and thyroid autoimmune disorders has been found by Giani et al. [16] and confirmed by Smyth et al. [17] . All of these studies have been carried out in breast cancer patients after mastectomy and before beginning any chemohormonal adjuvant therapy. A high prevalence of antithyroid peroxidase autoantibodies has been found in both treated and untreated breast cancer patients and the positive predictive value of serum thyroid peroxidase antibodies (TPO Ab) in breast cancer patients with aggressive disease has been reported [17] .
Only Jiskra et al. [18] , despite confirming a higher prevalence of TPO Ab in breast cancer patients, found no impact on relapse-free survival and overall survival; this discrepancy could be due to the relatively small number and heterogeneity of breast cancer patients in their study group. Recently Farahati et al. [19] reported a significantly lower frequency of distant metastases in a large cohort of breast cancer patients with serum TPO Ab positivity. The presence of serum TPO Ab, or clinical hypothyroidism, is associated with longer overall survival in patients with invasive breast carcinoma [20] . Overall, the results of previous studies suggest a positive correlation between thyroid disorders and the risk of developing invasive breast carcinoma [17, 21] .
On
18 F-FDG PET/CT, focal thyroid uptake is incidentally identified in healthy subjects and patients with cancer with an incidence of 0.6% to 3.3%, but in advanced breast cancer patients, Tateishi et al. [22] reported a higher incidence than what was observed in previous studies.
Our results in pretreatment breast cancer patients also suggest that a higher incidence of focal thyroid incidentaloma is observed in this patient cohort than in healthy women.
Focal thyroid FDG incidentalomas have been found to have a high risk of being malignant (14%-50%) [1, 13, 23] . The percentage of malignant thyroid incidentalomas in our study (23.9%) was similar to most previously reported rates [1, 12] , and lower than other reported data [24] . The current study was a retrospective observation study, and several focal thyroid incidentalomas were no evaluated with FNAB. Because of the high cost of FDG PET and the low incidence of thyroid FDG PET incidentalomas, we cannot use FDG PET prospectively to evaluate the incidence and malignancy rate of thyroid incidentalomas in the general population. A recent study has shown that the CT attenuation pattern of thyroid incidentalomas on dedicated PET/CT could provide additional information for the differentiation of malignant from benign disease [25] . The authors suggested that the 18 F-FDG uptake and the CT attenuation pattern, in addition to the SUV analysis, were helpful in characterizing focal thyroid incidentalomas.
There is also much evidence that estrogen has direct effects in thyroid cell lines originating from normal thyroid gland tissue and in thyroid carcinoma by ER-dependent mechanisms, such as the enhancement of proliferation, modulation of the sodium-iodide symporter and thyroglobulin gene expression, and upregulation of matrix metalloproteinase 9 production [26, 27] . We developed a hypothesis in which patients with breast cancer were more frequently diagnosed with thyroid cancers than healthy females. Based on the above findings, ER-positive breast cancers, in particular, may be correlated with thyroid carcinoma. We demonstrated that women with primary breast cancer have a higher incidence of focal thyroid incidentalomas 62 JungSunLee than healthy women. We also found that breast cancer with thyroid incidentalomas is most commonly ER-positive breast cancer or ductal carcinoma in situ.
Although several studies [28, 29] have investigated the expression of ER subtypes in thyroid cancers without consistent results as of yet, Huang et al. [30] reported that ERα may be a useful immunohistochemical marker for the differential diagnosis of papillary thyroid carcinoma. They also showed an association of the ER subtype expression with Ki-67 positivity and mutant p53 in female papillary thyroid carcinoma patients of reproductive age, suggesting that estrogen-activated ERα may mediate the stimulatory effects on papillary thyroid carcinoma growth and progression; in contrast, ERβ1 has some inhibitory effects. This study was not a prospective study of the relationship between breast cancer and thyroid disease or thyroid malignancy, resulting in a limited ability to estimate these relationships. In addition, further studies are required to evaluate the immunohistochemical markers, such as Ki-67 positivity, ER subtypes, and mutant p53, in both thyroid cancers with focal thyroid uptake incidentalomas and in breast cancer patients with focal thyroid incidentalomas.
In conclusion, this study has demonstrated that focal thyroid incidentalomas are more frequently detected with 18 
